Market capitalization | $1.28b |
Enterprise Value | $1.40b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.72 |
P/S ratio (TTM) P/S ratio | 1.58 |
P/B ratio (TTM) P/B ratio | 0.36 |
Revenue growth (TTM) Revenue growth | 24.76% |
Revenue (TTM) Revenue | $812.04m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
14 Analysts have issued a Tilray, Inc. Series 2 forecast:
14 Analysts have issued a Tilray, Inc. Series 2 forecast:
Aug '24 |
+/-
%
|
||
Revenue | 812 812 |
25%
25%
|
|
Gross Profit | 155 155 |
219%
219%
|
|
EBITDA | 9.68 9.68 |
117%
117%
|
EBIT (Operating Income) EBIT | -118 -118 |
36%
36%
|
Net Profit | -213 -213 |
85%
85%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Tilray, Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The Company is focused on medical cannabis research, cultivation, processing and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment sales consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment sales consist of hemp seed, hemp foods, board spectrum hemp extract containing CBD which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Nanaimo, Canada.
Head office | United States |
CEO | Irwin Simon |
Employees | 2,650 |
Founded | 2018 |
Website | www.tilray.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.